Document:

Exhibit 1013

		

			Exhibit 10.13

		

		

			 

		

		
			Executive Employment Agreement
		

		
			This Employment Agreement (the "Agreement") is made and entered into as of September 4, 2018 (the “Effective Date”) by and between K. Gary Barnette, PhD, an individual residing at 624 Walters Dr., Wake Forest, NC 27587 (the "Executive") and Veru Inc., a Wisconsin corporation with its corporate headquarters at 4400 Biscayne Blvd., Suite 888, Miami FL 33137 (the "Company").
		

		
			WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; 
		

		
			WHEREAS, the Executive desires to be employed by the Company on such terms and conditions; and 
		

		
			WHEREAS, it is a condition precedent of Executive’s employment hereunder that Executive sign this Agreement. 
		

		
			NOW, THEREFORE, in consideration of the mutual covenants, promises and obligations set forth herein, the parties agree as follows:
		

		
			1.    Employment At-Will; Start Date.  The Executive's employment hereunder shall be for no definite or determinable period of time and the Executive's employment hereunder may be terminated by either the Company or the Executive at any time and for any reason subject to the provisions of Section 5 below.  The start date for the Executive in this new role will be immediately upon execution of this Agreement by both Executive and Company.
		

		
			2.    Position and Duties.
		

		
			(a)    Position.  During the Executive’s employment with the Company, the Executive shall serve as Chief Scientific Officer, subject to the Company’s Board approval of the new role by resolution or consent.  In such position, the Executive shall have such duties, authority and responsibility as are customary for an executive in Executive’s position and such others as shall be determined from time to time by the Company’s Chairman, Chief Executive Officer and President (“CEO”).  The Executive shall report directly to the CEO. 
		

		
			(b)    Duties.  During the Executive’s employment with the Company pursuant to this Agreement, the Executive shall devote substantially all of his business time and attention to the performance of the Executive's duties hereunder and will not engage in any other business, profession or occupation for compensation or otherwise which would conflict or interfere with the performance of such services either directly or indirectly without the prior written consent of the CEO.  Notwithstanding the foregoing, the Executive will be permitted to (a) with the prior consent of the CEO and which consent can be withheld by the CEO in his discretion, act or serve 
		

		
			as a director, trustee, committee member or principal of any type of business, civic or charitable organization as long as such activities are disclosed in writing to the Company's CEO, and (b) purchase or own less than five percent (5%) of the publicly traded securities of any corporation; provided that, such ownership represents a passive investment and that the Executive is not a controlling person of, or a member of a group that controls, such corporation; provided further that, the activities described in clauses (a) and (b) do not interfere with the performance of the Executive's duties and responsibilities to the Company as provided hereunder, including, but not limited to, the obligations set forth in this Section 2.
		

		
			3.    Place of Performance.  The principal place of Executive's employment shall be: (i) Executive’s home office located at 624 Walters Dr., Wake Forest, NC 27587; or (ii) potentially in the future should the Company’s CEO and President request, and should the Executive mutually agree, the Company’s headquarters at 4400 Biscayne Blvd., Suite # 888, Miami FL 33137; any of (i) or (ii) preceding could be considered as Executive’s principal place of employment for purposes of this Agreement.  Should the Executive relocate to Miami at the Company’s request, the Company shall pay Executive’s reasonable relocation expenses.  Executive will be required to travel on Company business during the Executive’s employment with the Company.
		

		
			4.    Compensation.
		

		
			4.1    Base Salary.  Subject to section 5.2(b)(i) hereof, the Company shall pay the Executive an annual rate of base salary of three hundred thirty thousand dollars ($330,000) in periodic installments in accordance with the Company's customary payroll practices, but no less frequently than monthly.  The Executive's base salary shall be reviewed at least annually by the Company’s CEO, and the CEO may, but shall not be required to, increase the base salary during the Executive’s employment with the Company. The Executive's annual base salary, as in effect from time to time, is hereinafter referred to as "Base Salary".
		

		
			4.2    Annual Cash Incentive Bonus.
		

		 

 

		
			(a)    For each fiscal year during the Executive’s employment pursuant to this Agreement, the Executive shall be eligible to receive an annual cash incentive bonus equal to forty-five percent (45%) of his Base Salary based on meeting certain Company and personal goals to be mutually agreed upon by the Executive and the CEO (the "Annual Bonus"). However, the decision to provide any Annual Bonus and the amount and terms of any Annual Bonus shall be at the discretion of the Company’s CEO.
		

		
			(b)    The Annual Bonus, if any, will be paid no later than the end of the first quarter of the fiscal year after the fiscal year in which an Annual Bonus, if any, is awarded; provided, however, that in order to be entitled to an Annual Bonus the Executive must be employed by the Company on the date of payment thereof, except as expressly otherwise provided herein, such as section 5.2(a)(ii) in the event of termination by the Company without cause or by the Executive for good reason. 
		

		
			4.3    Equity Awards.  Executive is eligible to participate in the Veru Inc. 2018 Equity Incentive Plan (“Plan”).  The Board of Director Compensation Committee has approved and authorized a one-time “sign-on” grant to Executive on the Effective Date under the Plan of non-qualified stock options (the “Stock Options”) to purchase a total of 300,000 shares of the Company’s common stock, with the Stock Options vesting one-third per year for three years and having an exercise price equal to the closing price of the Company’s common stock on the Effective Date.  The grant of the Stock Options is subject to the terms and conditions of the stock option grant agreement and prospectus for the Plan.
		

		
			4.4    Employee Benefits.  During the Executive’s employment with the Company pursuant to this Agreement, the Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the Company, as in effect from time to time (collectively, "Employee Benefit Plans") on a basis that is at least as favorable as those provided to other similarly situated executives of the Company and to the extent consistent with applicable law, the terms of the applicable Employee Benefit Plans, and the Company’s policy for sharing the cost of such benefits as in effect from time to time. The Company reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole discretion, subject to the terms of such Employee Benefit Plans and applicable law.  Executive will be immediately eligible to participate in the US health, dental, vision, disability and life insurance programs of which the premiums are currently fully paid by the Company.  
		

		
			4.5    Vacation; Paid Time-off.  During the Executive’s employment with Company pursuant to this Agreement, the Executive will be entitled to accrue four weeks (4) paid vacation per fiscal year.  The Executive shall receive other paid time-off in accordance with the Company's policies for officers as such policies may exist from time to time.
		

		
			4.6    Business Expenses.  The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the Executive in connection with the performance of the Executive's duties hereunder in accordance with the Company's expense reimbursement policies and procedures. 
		

		
			4.7    Sign-On Bonus.  The Company shall pay Executive a one-time cash bonus of $50,000.00 on the next regularly scheduled payroll date following the one-month anniversary of Executive’s employment. 
		

		
			5.    Termination of Employment.  This Agreement and the Executive's employment hereunder are for no definite or determinable period of time and may be terminated by either the Company or the Executive at any time and for any reason subject to the provisions of this Section 5.  Upon termination of this Agreement and the Executive’s employment hereunder, the Executive shall be entitled to the compensation and benefits described in this Section 5 and shall have no further rights to any compensation or any other benefits from the Company or any of its affiliates. 
		

		
			5.1    Termination by the Company for Cause or by the Executive without Good Reason.
		

		
			(a)    The Executive's employment hereunder may be terminated by the Company immediately for Cause (as defined below) or by the Executive without Good Reason (as defined below).  If the Executive's employment is terminated by the Company for Cause or by the Executive without Good Reason, the Executive shall be entitled to receive:
		

		
			(i)    any accrued but unpaid Base Salary and accrued but unused vacation which shall be paid on the pay date immediately following the Termination Date (as defined below) in accordance with the Company's customary payroll procedures; 
		

		
			(ii)    any unpaid Annual Bonus with respect to any completed fiscal year immediately preceding the Termination Date, if the Executive was still employed by the Company on the last day of the first quarter of the fiscal year after the fiscal year in which an Annual Bonus, if any, was awarded; provided further that, if the Executive's employment is terminated by the Company for Cause, then any such unpaid Annual Bonus shall be forfeited;
		

		
			(iii)    reimbursement for unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company's expense reimbursement policy; and
		

		 

		

			2

		

 

		
			(iv)    such employee benefits (including equity compensation), if any, to which the Executive may be entitled under the Company's Employee Benefit Plans as of the Termination Date; provided, however, that, if the Executive’s employment is terminated by the Company for Cause, the Executive will not be entitled to any unvested equity and shall forfeit any vested equity compensation not already received by the Executive.
		

		
			Items 5.1(a)(i) through 5.1(a)(iv) are referred to herein collectively as the "Accrued Amounts".
		

		
			(b)    For purposes of this Agreement, "Cause" shall mean:
		

		
			(i)    the Executive's failure to perform his duties (other than any such failure resulting from incapacity due to physical or mental illness or disability);
		

		
			(ii)    the Executive's failure to comply with any valid and legal directive of the CEO;
		

		
			(iii)    the Executive's engagement in dishonesty, illegal conduct or misconduct, which is, in each case, injurious to the Company or its affiliates;
		

		
			(iv)    the Executive's embezzlement, misappropriation or fraud, whether or not related to the Executive's employment with the Company;
		

		
			(v)    the Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude or results in harm to the Company or its affiliates;
		

		
			(vi)    the Executive's breach of the duty of loyalty or breach of fiduciary duty;
		

		
			(vii)    the Executive's unauthorized disclosure of Confidential Information (as defined below);
		

		
			(viii)    Executive's material breach of any material obligation under this Agreement or any other written agreement between the Executive and the Company; or
		

		
			(ix)    any material failure by the Executive to comply with the Company's written policies or rules, as they may be in effect from time to time during the Executive’s employment with the Company.
		

		
			5.2    Termination by the Company Without Cause or by the Executive for Good Reason.
		

		
			(a)    This Agreement and the Executive's employment hereunder may be terminated by the Company without Cause or by the Executive for Good Reason in accordance with the provisions set forth herein.  In the event of such termination, the Executive shall be entitled to receive the Accrued Amounts and, subject to the Executive's compliance with Sections 6 through 9 of this Agreement and his execution of a general release of claims in favor of the Company and all of its related entities and individuals (the "Release"), which shall include a re-affirmation of Executive’s non-disparagement obligation and his obligation to comply with Sections 6 through 9 of this Agreement and such Release becoming effective within the number of days permitted under applicable law following the Termination Date (the “Release Effective Date”), the Executive shall be entitled to receive the following: 
		

		
			(i)    continued Base Salary for six (6) months following the Termination Date payable in equal installments in accordance with the Company's normal payroll practices, but no less frequently than monthly, which shall commence on the Company’s regular pay day for the pay period immediately following the pay period that includes the Release Effective Date;
		

		
			(ii)    any unpaid Annual Bonus with respect to any completed fiscal year immediately preceding the Termination Date if the Executive was still employed by the Company on the last day of the preceding fiscal year;
		

		
			(iii)    a pro-rated payment equal to the Executive’s target bonus for the year in which the Termination occurs as defined in section 4.2(a) hereof multiplied by the percentage of days the Executive was employed by the Company in the year of termination, and payable as and when such bonuses are normally paid for other executives of the Company; and (iv)    if the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") or comparable State continuation law, the Company shall reimburse the Executive for the difference between the monthly COBRA or comparable State continuation law premium paid by the Executive for himself and his dependents and the monthly premium amount paid by similarly situated active executives.  Such reimbursement shall be paid to the Executive on the fifteenth of the month immediately following the month in which the Executive timely remits the premium payment.  The Executive shall be eligible to receive such reimbursement until the earliest of:  (i) the six (6) 
		

		 

		

			3

		

 

		month anniversary of the Termination Date; (ii) the date the Executive (in the case of his) or any of his dependents (in the case of such dependent) is no longer eligible to receive COBRA or comparable State law continuation coverage; and (iii) the date on which the Executive (in the case of his) or any of his dependents (in the case of such dependent) becomes eligible to receive substantially similar coverage from another employer or other source.
		

		
			(b)    For purposes of this Agreement, "Good Reason" shall mean the occurrence of any of the following, in each case during the Executive’s employment under this Agreement without the Executive's written consent:
		

		
			(i)    a reduction in the Executive's Base Salary of more than ten percent (10%) other than a general reduction in Base Salary that affects all similarly situated executives in substantially the same proportions;
		

		
			(ii)    a relocation of the Executive's principal place of employment outside of the metropolitan area where the Executive currently has his principal office;
		

		
			(iii)    any material breach by the Company of any material provision of this Agreement; or 
		

		
			(iv)    a material, adverse change in the Executive's authority, duties or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law) taking into account the Company's size, status as a public company and capitalization as of the date of this Agreement.
		

		
			The Executive cannot terminate his employment for Good Reason unless he has provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within thirty (30) days of the initial existence of such grounds, and the Company has had thirty (30) days from the date on which such notice is provided to cure such circumstances.  If the Company has not cured such Good Reason within thirty (30) days of such notice, the Executive shall have up to thirty (30) days after such cure period to terminate his employment hereunder for Good Reason.  If the Executive does not provide written notice to the Company to terminate his employment for Good Reason within the time period specified herein, then the Executive will be deemed to have waived his right to terminate for Good Reason with respect to such grounds.
		

		
			5.3    Death or Disability.
		

		
			(a)    The Executive's employment hereunder shall terminate automatically upon the Executive's death during the Executive’s employment under this Agreement, and the Company may terminate the Executive's employment on account of the Executive's Disability (as defined below). 
		

		
			(b)    If the Executive's employment is terminated during the Employment Term on account of the Executive's death or Disability, the Executive (or the Executive's estate and/or beneficiaries, as the case may be) shall be entitled to receive the following:
		

		
			(i)    pay for any of the Executive’s accrued but unpaid Base Salary and the Executive’s accrued but unused vacation as of the date of death or Disability; 
		

		
			(ii)    any earned but unpaid Annual Bonus with respect to any completed fiscal year immediately preceding the Executive’s date of death or Disability, if the Executive was still employed by the Company on the last day of the preceding fiscal year;
		

		
			(iii)    reimbursement for unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company's expense reimbursement policy; and
		

		
			(iv)    such employee benefits (including equity compensation), if any, to which the Executive may be entitled under the Company's Employee Benefit Plans as of the date of the Executive’s death or Disability.
		

		
			(c)    For purposes of this Agreement, “Disability” shall mean the Executive is entitled to receive long-term disability benefits under the Company's long-term disability plan, or if there is no such plan, the Executive's inability, due to physical or mental incapacity, to substantially perform all of the essential duties and responsibilities under this Agreement, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period or one hundred twenty (120) consecutive days; provided however, in the event the Company temporarily replaces the Executive, or transfers the Executive's duties or responsibilities to another individual on account of the Executive's inability to perform such duties due to a mental or physical incapacity which is, or is reasonably expected to become, a Disability, then the Executive's employment shall not be deemed terminated by the Company and the Executive shall not be able to resign with Good Reason as a result thereof.  Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot 
		

		 

		

			4

		

 

		agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement.
		

		
			5.4    Change in Control Termination.  
		

		
			(a)    Notwithstanding any other provision contained herein, if the Executive's employment hereunder is terminated by the Executive for Good Reason or by the Company without Cause (other than on account of the Executive's death or Disability) within six (6) months following a Change in Control, the Executive shall be entitled to receive, subject to the Executive's compliance with Sections 6 through 9 of this Agreement and his execution of the Release and reaffirmations referred to in Section 5.2, the following:
		

		
			(i)    all items of compensation set forth in Section 5.2(a)(i-iv); and
		

		
			(ii)    acceleration of unvested equity compensation in accordance with the terms of the Company’s applicable equity compensation plans and grant agreements.
		

		
			(b)    For purposes of this Agreement, "Change in Control"  shall have the meaning set forth in the Company’s applicable equity plans and grant agreements.
		

		
			5.5    Notice of Termination.  Any termination of the Executive's employment hereunder by the Company or by the Executive during the Executive’s employment under this Agreement (other than termination pursuant to Section 5.3(a) on account of the Executive's death) shall be communicated by written notice of termination ("Notice of Termination") to the other party hereto in accordance with Section 25 of this Agreement.  The Notice of Termination shall specify: 
		

		
			(a)    The termination provision of this Agreement relied upon; 
		

		
			(b)    To the extent applicable, the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated; and
		

		
			(c)    The applicable Termination Date.
		

		
			5.6    Termination Date.  The Executive's "Termination Date"  shall be: 
		

		
			(a)    If the Executive's employment hereunder terminates on account of the Executive's death, the date of the Executive's death; 
		

		
			(b)    If the Executive's employment hereunder is terminated on account of the Executive's Disability, the date that it is specified in the Company’s Notice of Termination after it is determined that the Executive has a Disability;
		

		
			(c)    If the Company terminates the Executive's employment hereunder for Cause, the date the Notice of Termination is delivered to the Executive;
		

		
			(d)    If the Company terminates the Executive's employment hereunder without Cause, the date specified in the Notice of Termination, which shall be no less than ten (10) business days following the date on which the Notice of Termination is delivered; provided that during said notice period, the Company shall have the right to change or eliminate the Executive’s duties within its discretion, which shall not be deemed a Good Reason hereunder;
		

		
			(e)    If the Executive terminates  employment hereunder with or without Good Reason, the date specified in the Executive's Notice of Termination, which shall be no less than ten (10) business days following the date on which the Notice of Termination is delivered; provided that, the Company may waive all or any part of the ten (10) day notice period without further accrual or payment of salary or benefits upon written notice to the Executive, and the Executive's Termination Date shall be the date determined in such notice by the Company;
		

		
			Notwithstanding anything contained herein, the Termination Date shall not occur until the date on which the Executive incurs a "separation from service" within the meaning of Section 409A.
		

		
			5.7    Resignation of All Other Positions.  Upon termination of the Executive's employment hereunder for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as an officer or member of the board of directors (or a committee thereof) of the Company or any of its affiliates.
		

		 

		

			5

		

 

		
			5.8    Section 280G.
		

		
			(a)    If any of the payments or benefits received or to be received by the Executive (including, without limitation, any payment or benefits received in connection with a Change in Control or the Executive's termination of employment, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement, or otherwise) (all such payments collectively referred to herein as the “280G Payments”) constitute “parachute payments” within the meaning of Section 280G of the Code and would, but for this Section 5.8, be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then prior to making the 280G Payments, a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the 280G Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the 280G Payments are limited to the extent necessary to avoid being subject to the Excise Tax.  Only if the amount calculated under (i) above is less than the amount under (ii) above will the 280G Payments be reduced to the minimum extent necessary to ensure that no portion of the 280G Payments is subject to the Excise Tax. "Net Benefit" shall mean the present value of the 280G Payments net of all federal, state, local, foreign income, employment and excise taxes. Any reduction made pursuant to this Section 5.9 shall be made in a manner determined by the Company that is consistent with the requirements of Section 409A.
		

		
			(b)    Unless the Company and the Executive otherwise agree, all calculations and determinations under this Section 5.8 shall be made by an independent accounting firm whose determinations shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by this Section 5.8, the accounting firm may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the Code.  The Company and the Executive shall furnish the accounting firm with such information and documents as the accounting firm may reasonably request in order to make its determinations under this Section 5.8. The Company shall bear all costs the accounting firm may reasonably incur in connection with its services as contemplated by this provision. 
		

		
			6.    Cooperation.  The parties agree that certain matters in which the Executive will be involved during his employment with the Company may necessitate the Executive's cooperation in the future.  Accordingly, following the termination of the Executive's employment for any reason, to the extent reasonably requested by the Company’s CEO, the Executive shall cooperate with the Company in connection with matters arising out of the Executive's service to the Company; provided that, the Company shall make reasonable efforts to minimize disruption of the Executive's other activities.  The Company shall reimburse the Executive for reasonable expenses incurred in connection with such cooperation and, to the extent that the Executive is required to spend substantial time on such matters, the Company shall compensate the Executive at an hourly rate based on the Executive's Base Salary on the Termination Date.
		

		
			7.    Confidential Information.  The Executive understands and acknowledges that during his employment with the Company, he will have access to and learn about Confidential Information, as defined below.
		

		
			7.1    Confidential Information Defined; Restrictions.
		

		
			(a)    Definition.
		

		
			For purposes of this Agreement, "Confidential Information" includes, but is not limited to, all information not known to the public, in spoken, printed, electronic or any other form or medium, relating directly or indirectly to:  business processes, methods, policies, plans, publications, documents, research, operations, strategies, techniques, contracts, transactions, potential transactions, negotiations, pending negotiations, know-how, trade secrets, computer programs, computer software, applications, operating systems,  software design, web design, work-in-process, databases, manuals, records, articles, systems, material, sources of material, supplier information, vendor information, financial information, accounting information, accounting records, legal information, marketing information, advertising information, pricing information, design information, payroll information and staffing information, personnel information, employee lists, supplier lists, vendor lists, developments, reports, internal controls, security procedures, graphics, drawings, sketches, market studies, sales information, revenue, costs, formulae, product plans, designs, models, ideas, inventions, unpublished patent applications, discoveries, experimental processes, experimental results, specifications, customer or client information or lists, manufacturing information, distributor lists, and buyer lists of the Company, and any information about or from any existing or prospective customer, supplier, investor or other associated third party, or of any other person or entity that has entrusted information to the Company in confidence. 
		

		
			The Executive understands that the above list is not exhaustive, and that Confidential Information also includes other information that is marked or otherwise identified as confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is known or used. 
		

		
			The Executive understands and agrees that Confidential Information includes information developed by him in the course of his employment by the Company as if the Company furnished the same Confidential Information to the Executive in the first instance. Confidential Information shall not include (i) information that is or becomes publicly known to others who are not under 
		

		 

		

			6

		

 

		a confidentiality obligation to the Company, without breach by the Executive of Section 7.1 (c) below or (ii) information provided to the Executive by a third party who is not under a confidentiality obligation benefitting the Company or others with respect to the information.  The Executive understands and agrees that all Company Confidential Information constitutes trade secrets under Florida law and any other applicable law.
		

		
			(b)    Company Creation and Use of Confidential Information.
		

		
			The Executive understands and acknowledges that the Company has invested, and continues to invest, substantial time, money and specialized knowledge into developing its resources, creating a customer base, generating customer and potential customer lists, training its employees (including the Executive), and improving its offerings in the field of diversified drugs, therapeutics and medical devices for men’s and women’s reproductive health, urology and oncology.  The Executive understands and acknowledges that as a result of these efforts, the Company has created, and continues to use and create Confidential Information.  This Confidential Information provides the Company with a competitive advantage over others in the marketplace. 
		

		
			(c)    Disclosure and Use Restrictions.
		

		
			The Executive agrees and covenants:  (i) to treat all Confidential Information as strictly confidential; (ii) not to directly or indirectly disclose, publish, communicate or make available Confidential Information, or allow it to be disclosed, published, communicated or made available, in whole or part, to any entity or person whatsoever (including other employees of the Company) not having a need to know and authority to know and use the Confidential Information in connection with the business of the Company and, in any event, not to anyone outside of the direct employ of the Company except as required in the performance of the Executive's authorized employment duties to the Company or with the prior consent of the CEO acting on behalf of the Company in each instance (and then, such disclosure shall be made only within the limits and to the extent of such duties or consent); and (iii) not to access or use any Confidential Information, and not to copy any documents, records, files, media or other resources containing any Confidential Information, or remove any such documents, records, files, media or other resources from the premises or control of the Company, except as required in the performance of the Executive's authorized employment duties to the Company or with the prior consent of the CEO acting on behalf of the Company in each instance (and then, such disclosure shall be made only within the limits and to the extent of such duties or consent). Nothing herein shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation or order. The Executive shall promptly provide written notice of any such order to Company’s Executive Vice President-Legal.  While complying with this Section 7.1 to the greatest extent possible, nothing herein prohibits the Executive from reporting possible violations of federal law or regulation to any governmental agency from or making other disclosures under the whistleblower provisions of federal or state law or regulation. Executive is not required to notify the Company if Executive makes such reports or disclosures.
		

		
			The Executive understands and acknowledges that his obligations under this Agreement with regard to any particular Confidential Information shall commence immediately upon the Executive first having access to such Confidential Information (whether before or after he begins employment by the Company) and shall continue during and after his employment by the Company until such time as such Confidential Information has become public knowledge other than as a result of the Executive's breach of this Agreement or breach by those acting in concert with the Executive or on the Executive's behalf.  
		

		
			(d)    Defend Trade Secrets Act Notice
		

		
			Executive is hereby notified in accordance with the Defend Trade Secrets Act of 2016 that he will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (i) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.  Executive is further notified that if Executive files a lawsuit for retaliation by an employer for reporting a suspected violation of law, Executive may disclose the employer's trade secrets to Executive’s attorney and use the trade secret information in the court proceeding if Executive: (i) files any document containing the trade secret under seal; and (ii) does not disclose the trade secret, except pursuant to court order.
		

		
			8.    Restrictive Covenants.
		

		
			8.1    Acknowledgement.  The Executive understands that the nature of the Executive's position gives him access to and knowledge of Confidential Information and places him in a position of trust and confidence with the Company. The Executive understands and acknowledges that the intellectual services he provides to the Company are unique, special or extraordinary because of his knowledge, experience, training and expertise in the areas and disciplines for which the Company has chosen to employ him.
		

		 

		

			7

		

 

		
			The Executive further understands and acknowledges that the Company's ability to reserve these for the exclusive knowledge and use of the Company is of great competitive importance and commercial value to the Company, and that improper use or disclosure by the Executive is likely to result in unfair or unlawful competitive activity.
		

		
			8.2    Non-competition.  Because of the Company’s legitimate business interest as described herein and the good and valuable consideration offered to the Executive, during the Executive’s employment with the Company and for the period of two (2) years beginning on the last day of the Executive's employment with the Company (the “Restricted Period”), whether employment is terminated at the option of the Executive or the Company, the Executive agrees and covenants not to engage in Prohibited Activity that is, or is expected to be, competitive with the Company’s drug products, female condom, diversified drugs, and therapeutics and medical device businesses in the fields of men’s and women’s reproductive health, urology and oncology (collectively the “Prohibited Field”).  For purposes of this Agreement, the Prohibited Field is limited to products and/or services for which the Executive participated in the development, planning, testing, sale, marketing or evaluation of on behalf of the Company in or during any part of the last 24 months of the Executive’s employment with the Company or for which the Executive supervised one of or more of the Company’s employees, units, divisions, or departments in doing so.
		

		
			8.3    Prohibited Activity.  For purposes of this Section 8, "Prohibited Activity" is activity in which the Executive contributes his knowledge, services and/or financial support, directly or indirectly, in whole or in part, as an owner, operator, manager, advisor, lender, investor, consultant, agent, employee, partner, director, stockholder, officer, volunteer, intern or any other similar capacity to an entity or person engaged in the same or similar business as the Company, including those engaged in the Prohibited Field, within the United States and any other countries in which the Company sells, markets and/or develops its products and/or services.  Prohibited Activity also includes activity that may require or inevitably requires disclosure of Company trade secrets or other Confidential Information.  Nothing herein shall prohibit the Executive from purchasing or owning less than five percent (5%) of the publicly traded securities of any corporation or from continuing to own a minority interest in a private company to the extent existing and disclosed to the Company in writing prior to the Effective Date, provided that such ownership represents a passive investment and that the Executive is not a controlling person of, or a member of a group that controls, such corporation.
		

		
			8.4    Non-solicitation of Employees. The Executive agrees that the Company has made a substantial investment in its employees in order to retain their services and valuable contribution to its business, and to minimize turnover and recruitment training time and cost.  Therefore, to protect this legitimate interest of the Company, the Executive agrees and covenants not to directly or indirectly, on Executive’s own behalf or on behalf of any other person or entity, solicit, hire, recruit, attempt to hire or recruit, or induce the termination of employment of any employee of the Company during the Restricted Period.
		

		
			8.5    Non-solicitation of Customers.  The Executive agrees that the Company has made a substantial investment in order to develop and maintain valuable relationships with its customers and prospective customers.  The Executive further agrees that the Company has long-standing relationships with its customers and that but for the Executive’s employment with the Company, the Executive would not have had access to or Confidential Information about its customers.  Executive understands and acknowledges that because of the Executive's experience with and relationship to the Company he will have access to the Company’s customers and prospective customers and learn about much or all of the Company's customer information which is confidential and/or compiled in a confidential manner.  "Customer Information" includes, but is not limited to, names, phone numbers, addresses, e-mail addresses, order history, order preferences, chain of command, pricing information, profitability, sales and marketing strategy, and other information identifying facts and circumstances specific to the customer or prospective customer and relevant to sales or services provided by the Company, whether Confidential Information or otherwise.
		

		
			The Executive understands and acknowledges that loss of customer or prospective customer relationships and/or goodwill will cause significant and irreparable harm to the Company. 
		

		
			Therefore, to protect these legitimate interests of the Company, Executive agrees and covenants, during Restricted Period, not to directly or indirectly, on Executive’s own behalf or on behalf of any other person or entity, solicit, contact (including but not limited to e-mail, regular mail, express mail, telephone, fax, and instant message), attempt to contact or meet with or provide any products or services to the Company's customers or prospective customers for purposes of offering or providing goods or services similar to or competitive with those offered by the Company.
		

		
			The restrictions in this Section 8.5 shall only apply to:
		

		
			(a)    Customers or prospective customers the Executive contacted in any way during the past one (1) year prior to the Executive’s last day of employment with the Company; or
		

		
			(b)    Customers or prospective customers about whom the Executive has or had access to trade secret or other Confidential Information; or
		

		 

		

			8

		

 

		
			(c)    Customers under the Executive’s supervisory or sales purview who became customers during the Executive's employment with the Company.
		

		
			8.6    Non-interference with Other Business Relationships.  The Executive agrees and covenants, during the Restricted Period, not to directly or indirectly, on Executive’s own behalf or on behalf of any other person, interfere with or cause disruption in any way to the Company’s contracts or relationships with its business partners, including, but not limited to, vendors, suppliers, manufacturing sources, and IT consultants.
		

		
			8.7    Extension of Restricted Period.  The Executive agrees that should he breach any of his covenants in this Section 8, the Restricted Period shall be extended by the length of any period of such breach.
		

		
			9.    Non-disparagement. The Executive agrees and covenants that he will not at any time make, publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments or statements concerning the Company or its businesses, or any of its employees, officers, directors, and existing and prospective customers, suppliers, investors and other associated third parties. 
		

		
			This Section 9 does not, in any way, restrict or impede the Executive from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation or order. The Executive shall promptly provide written notice of any such order to Company’s EVP Legal.
		

		
			10.    Acknowledgement. The Executive acknowledges and agrees that the services to be rendered by him to the Company are of a special and unique character; that the Executive will obtain knowledge and skill relevant to the Company's industry, methods of doing business and marketing strategies by virtue of the Executive's employment; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable and reasonably necessary to protect the legitimate business interests of the Company. 
		

		
			The Executive further acknowledges and agrees that the amount of his compensation hereunder reflects, in part, substantial consideration for his obligations and the Company's rights under Sections 7 through 9 of this Agreement; that he has no expectation of any additional compensation, royalties or other payment of any kind not otherwise referenced herein in connection herewith; that he will not be subject to undue hardship by reason of his full compliance with the terms and conditions of Sections 7 through 9 of this Agreement or the Company's enforcement thereof.
		

		
			11.    Remedies. In the event of a breach or threatened breach by the Executive of any of Sections 7 through 9 of this Agreement, the Executive hereby consents and agrees that the Company shall be entitled to seek, in addition to other available remedies, a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of posting any bond or other security or of showing any actual damages or that money damages would not afford an adequate remedy.  The aforementioned equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages or other available forms of relief.  In the event the Executive breaches any of his obligations contained in any of Sections 7 through 9, the Company shall be entitled to an award of its costs, reasonable attorneys’ and expert witness fees, and out-of-pocket expenses incurred in obtaining a judgment or order against the Executive in addition to any to other relief awarded to the Company.
		

		
			12.    Waiver of Defenses.  The Executive agrees that in the event the Company brings an action for injunctive or other relief for any alleged violation by the Executive of any of Sections 7 through 9 above, the Executive will not raise any defense to such action or the relief sought by the Company on the grounds that the Company terminated the Executive’s employment in bad faith or committed any breach of this Agreement or any other agreement between the parties, and Executive hereby waives any such defenses in any such action.
		

		
			13.    Work Product and Intellectual Property Protection.
		

		
			13.1    Work Product. The Executive acknowledges and agrees that all right, title and interest in and to all writings, works of authorship, technology, inventions, discoveries, processes, techniques, methods, ideas, concepts, research, proposals, materials and all other work product of any nature whatsoever, that are created, prepared, produced, authored, edited, amended, conceived or reduced to practice by the Executive individually or jointly with others during the period of his employment by the Company and relate in any way to the business or contemplated business, products, activities, research or development of the Company or result from any work performed by the Executive for the Company (in each case, regardless of when or where prepared or whose equipment or other resources is used in preparing the same) all rights and claims related to the foregoing, and all printed, physical and electronic copies, and other tangible embodiments thereof (collectively, "Work Product"),  as well as any and all rights in and to US and foreign (a) patents, patent disclosures and inventions (whether patentable or not), (b) trademarks, service marks, trade dress, trade names, logos, corporate names and domain names, and other similar designations of source or origin, together with the goodwill symbolized by any of the foregoing, (c) copyrights and copyrightable works (including computer programs), and rights in data and databases, (d) trade secrets, know-how and other confidential information, and (e) all other intellectual property rights, in each case whether registered or 
		

		 

		

			9

		

 

		unregistered and including all registrations and applications for, and renewals and extensions of, such rights, all improvements thereto and all similar or equivalent rights or forms of protection in any part of the world (collectively, "Intellectual Property Rights"),  shall be the sole and exclusive property of the Company.
		

		
			13.2    Work Made for Hire; Assignment. The Executive acknowledges that, by reason of being employed by the Company at the relevant times, to the extent permitted by law, all of the Work Product consisting of copyrightable subject matter is "work made for hire" as defined in 17 U.S.C. § 101 and such copyrights are therefore owned by the Company. To the extent that the foregoing does not apply, the Executive hereby irrevocably assigns to the Company, for no additional consideration, the Executive's entire right, title and interest in and to all Work Product and Intellectual Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation or dilution thereof, and all rights corresponding thereto throughout the world.  The Company’s rights under this Section 13.2 are in addition to, and not in lieu of, any substantive protections the Company may have under any law.
		

		
			13.3    Further Assurances; Power of Attorney. During and after his employment, the Executive agrees to reasonably cooperate with the Company to (a) apply for, obtain, perfect and transfer to the Company the Work Product as well as any and all Intellectual Property Rights in the Work Product in any jurisdiction in the world; and (b) maintain, protect and enforce the same, including, without limitation, giving testimony and executing and delivering to the Company any and all applications, oaths, declarations, affidavits, waivers, assignments and other documents and instruments as shall be requested by the Company. The Executive hereby irrevocably grants the Company power of attorney to execute and deliver any such documents on the Executive's behalf in his name and to do all other lawfully permitted acts to transfer the Work Product to the Company and further the transfer, prosecution, issuance and maintenance of all Intellectual Property Rights therein, to the full extent permitted by law, if the Executive does not promptly cooperate with the Company's request (without limiting the rights the Company shall have in such circumstances by operation of law). The power of attorney is coupled with an interest and shall not be affected by the Executive's subsequent incapacity.
		

		
			13.4    No License. The Executive understands that this Agreement does not, and shall not be construed to grant the Executive any license or right of any nature with respect to any Work Product or Intellectual Property Rights or any Confidential Information, materials, software or other tools made available to him by the Company.
		

		
			14.    Security.
		

		
			14.1    Security and Access.  The Executive agrees and covenants (a) to comply with all Company security policies and procedures as in force from time to time including without limitation those regarding computer equipment, telephone systems, facilities access, key cards, access codes, Company intranet, internet, social media and instant messaging systems, computer systems, e-mail systems, computer networks, document storage systems, software, data security, encryption, firewalls, passwords and any and all other Company IT resources and communication technologies (collectively, "Facilities and Information Technology Resources"); (b) not to access or use any Facilities and Information Technology Resources except as authorized by the Company; and (iii) not to access or use any Facilities and Information Technology Resources in any manner after the termination of the Executive's employment by the Company, whether termination is voluntary or involuntary. The Executive agrees to notify the Company promptly in the event he learns of any violation of the foregoing by others, or of any other misappropriation or unauthorized access, use, reproduction or reverse engineering of, or tampering with any Facilities and Information Technology Resources or other Company property or materials by others.
		

		
			14.2    Exit Obligations.  Upon (a) voluntary or involuntary termination of the Executive's employment or (b) the Company's request at any time during the Executive's employment, the Executive shall (i) provide or return to the Company any and all Company property, including but limited to, keys, access cards, identification cards, Company credit cards, computers smartphones, equipment, manuals, reports, files, books, compilations, work product, e-mail messages, thumb drives and other removable information storage devices, hard drives, and data and all Company  documents and materials belonging to the Company and stored in any fashion, including but not limited to those that constitute or contain any Confidential Information or Work Product, that are in the possession or control of the Executive, whether they were provided to the Executive by the Company or any of its business associates or created by the Executive in connection with his employment by the Company; and (ii) delete or destroy all copies of any such documents and materials not returned to the Company that remain in the Executive's possession or control, including those stored on any non-Company devices, networks, storage locations and media in the Executive's possession or control.
		

		
			15.    Publicity.  The Executive hereby irrevocably consents to any and all uses and displays, by the Company and its agents, representatives and licensees, of the Executive's name, voice, likeness, image, appearance and biographical information in, on or in connection with any pictures, photographs, audio and video recordings, digital images, websites, television programs and advertising, other advertising and publicity, sales and marketing brochures, books, magazines, other publications, CDs, DVDs, tapes and all other printed and electronic forms and media throughout the world, at any time during or after the period of his employment by the Company, for all legitimate commercial and business purposes of the Company ("Permitted Uses") without further consent from or royalty, payment or other compensation to the Executive. The Executive hereby forever waives and releases the Company and its directors, officers, employees and agents from any and all claims, actions, damages, losses, costs, expenses and liability of any kind, 
		

		 

		

			10

		

 

		arising under any legal or equitable theory whatsoever at any time during or after the period of his employment by the Company, arising directly or indirectly from the Company's and its agents', representatives' and licensees' exercise of their rights in connection with any Permitted Uses.
		

		
			16.    Governing Law; Jurisdiction and Venue. This Agreement, for all purposes, shall be construed in accordance with the laws of the State of Florida without regard to conflicts of law principles. Any action or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the state of Florida, county of Miami-Dade.  The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive any defenses relating to personal jurisdiction, improper venue or inconvenient forum with respect to any such action or proceeding.
		

		
			17.    Entire Agreement.  Unless specifically provided herein, this Agreement contains all of the understandings and representations between the Executive and the Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter.  The parties mutually agree that the Agreement can be specifically enforced in court and can be cited as evidence in legal proceedings alleging breach of the Agreement. 
		

		
			18.    Modification and Waiver.  No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by the Executive and by the CEO of the Company.  No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power or privilege.
		

		
			19.    Severability.  Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this Agreement. 
		

		
			The parties further agree that any such court is expressly authorized and shall modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law. 
		

		
			The parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event, should one or more of the provisions of this Agreement be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall be construed as if such invalid, illegal or unenforceable provisions had not been set forth herein.
		

		
			20.    Captions.  Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.
		

		
			21.    Counterparts.  This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.
		

		
			22.    Section 409A.
		

		
			22.1    The Parties’ Intent.  The intent of the Parties is that payments and benefits under this Agreement comply with or be exempt for Section 409A of the Code and the regulations and guidance promulgated thereunder (collectively, “Code Section 409A”), and this Agreement and any associated documents shall be interpreted and construed in a manner the establishes an exemption from (or compliance with Code Section 409A).  Any terms of this Agreement that are undefined or ambiguous shall be interpreted in a manner that complies with Code Section 409A to the extent necessary to comply with Code Section 409A.  If for any reason, such imprecision in drafting any provision of this Agreement (or any award of compensation, including, without limitation, equity compensation or benefits) does not accurately reflect its intended establishment as an exemption from (or compliance with Code Section 409A), as demonstrated by consistent interpretations or other evidence of intent, such provision shall be considered ambiguous as to its exemption from (or compliance with) Code Section 409A and shall be interpreted in a manner consistent with such intent, as determined in the discretion of the Company.
		

		
			22.2    Separation from Service.  A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for any payment of any amounts or benefits that the Company determines may be considered 
		

		 

		

			11

		

 

		nonqualified deferred compensation under Code Section 409A upon or following termination of employment unless such termination is a “Separation of Service” with the meaning of Code Section 409A, and, for purposes of any such provision of this Agreement, references to a “termination,” “termination of employment” or the like shall mean a separation of service.  The determination of whether and when a separation of service has occurred for purposes of this Agreement shall be made in in accordance with the presumptions set forth in Section 1.409A-1(h) of the Treasury Regulations.
		

		
			22.3    Reimbursements.  Any reimbursements and in-kind benefits provided under this Agreement that constitute deferred compensation within the meaning of Code Section 409A shall be made or provided in accordance with the requirements of Code Section 409a, including, without limitation, that in no event shall any fees, expenses or other amounts eligible to be reimbursed by the Company under this Agreement be paid later that the last day of the calendar year next following the calendar year in which the applicable fees, expenses or other amounts were incurred.
		

		
			22.4    Payments.  For purposes of Code Section 409A, the Executive’s right to receive any installment payments shall be treated as a right to receive a series of separate and distinct payments.  Whenever a payment under this Agreement specifies a payment period with reference to a number of days (for example, “payment shall be made within thirty (30) days following the date of termination), the actual date of payment within the specified period shall be within the sole discretion of the Company.  In no event may the Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement, to the extent that such payment is subject to Code Section 409A.
		

		
			22.5    No Company Warranties.  The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions in this Agreement are determined to constitute deferred compensation subject to Code Section 409A but do not satisfy an exemption from, or the conditions of, Code Section 409A.
		

		
			23.    Notification to Subsequent Employer.  When the Executive's employment with the Company terminates, the Executive agrees to notify any subsequent employer of the restrictive covenants sections contained in this Agreement.  The Executive will also deliver a copy of such notice to the Company before the Executive commences employment with any subsequent employer.  In addition, the Executive authorizes the Company to provide a copy of sections 7 to 12 of this Agreement to third parties, including but not limited to, the Executive's subsequent, anticipated or possible future employer.
		

		
			24.    Successors and Assigns. This Agreement is personal to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns.
		

		
			25.    Notice.  Notices and all other communications provided for in this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested, or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like notice):
		

		
			﻿
		

		
			If to the Company:
		

		
			Veru Inc.
		

		
			4400 Biscayne Blvd
		

		
			Suite 888
		

		
			Miami, FL 33137
		

		
			Attention:  EVP Legal
		

		
			﻿
		

		
			If to the Executive: 
		

		
			K. Gary Barnette
		

		
			624 Walters Dr.
		

		
			Wake Forest, NC 27587
		

		
			﻿
		

		
			26.    Representations of the Executive.  The Executive represents and warrants to the Company that:
		

		
			(a)    The Executive's acceptance of employment with the Company and the performance of his duties hereunder will not conflict with or result in a violation of, a breach of, or a default under any contract, agreement or understanding to which he is a party or is otherwise bound; and 
		

		
			(b)    The Executive's acceptance of employment with the Company and the performance of his duties hereunder will not violate any non-solicitation, non-competition or other similar covenant or agreement of a prior employer.
		

		 

		

			12

		

 

		
			27.    Withholding.  The Company shall have the right to withhold from any amount payable hereunder any federal, state and/or local taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation.
		

		
			28.    Survival.  Upon the termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such termination to the extent necessary to carry out the intentions of the parties under this Agreement.
		

		
			29.    Acknowledgement of Full Understanding.  THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF HIS CHOICE BEFORE SIGNING THIS AGREEMENT. 
		

		
			﻿
		

		
			IN WITNESS WHEREOF, the parties hereto have entered into this Agreement in Miami, Florida as of the date first written above.
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

			
					
						 

					
					
						 

					
						 

					
						 

				
	
					
						﻿

					
					
						VERU INC.

					
						 

					
						 

				
	
					
						﻿

					
					
						_______________________

					
						Mitchell S. Steiner, MD, FACS

					
						Chairman, President and CEO

				
	
					
						﻿

					
					
						 

					
						K. Gary Barnette, PhD

					
						 

					
						_______________________

					
						Executive

				

		
			﻿
		

		 

		

			13Exhibit 1032

		

			Exhibit 10.32

		

		

			 

		

		
			CONSULTING AGREEMENT
		

		
			This Consulting Agreement (“Agreement”) is made and entered into as of the 13th day of September, 2018 (the “Effective Date”) by and between Robert Getzenberg, Ph.D., an individual residing at 358 N. Island Drive, # 106, Memphis TN 38103 (the "Consultant") and Veru Inc., a Wisconsin corporation whose principal place of business is located at 4400 Biscayne Blvd., Suite 888, Miami FL 33137 (the "Company"). 
		

		
			﻿
		

		
			Recitals
		

			
	
			
				 A.
			

			
	
			
			The Company is engaged in, among other things, the commercialization and development of proprietary pharmaceuticals and medical device health products.  

			
	
			
				 B.
			

			
	
			
			Consultant previously entered into an Executive Employment Agreement dated March 21, 2018 with Company (“Employment Agreement”) pursuant to which Consultant was appointed the Company’s Chief Scientific Officer.  

		
			﻿
		

			
	
			
				 C.
			

			
	
			
			Consultant notified the Company in June, 2018 that he was voluntarily resigning his position as Chief Scientific Officer and terminating his employment with Company and the parties agreed that Consultant’s resignation as Chief Scientific Officer would be made effective as of September 4, 2018 while his resignation as an employee would be made effective as of September 14, 2018 (“Resignation Date”);  

		
			﻿
		

			
	
			
				 D.
			

			
	
			
			Notwithstanding Consultant’s resignation of employment, and subject to the terms and conditions of this Agreement, the Company desires to engage the services of the Consultant, and the Consultant desires to provide certain consulting and advisory services to the Company as an independent contractor.

		
			﻿
		

		
			﻿
		

		
			Agreement
		

		
			In consideration of the Recitals and the mutual covenants contained in this Agreement the Company and the Consultant agree as set forth below.
		

			
	
			
				 1.
			Definitions.  In addition to terms defined elsewhere in this Agreement, when used in this Agreement the terms set forth below shall have the meanings indicated.

		
			“Affiliate” means any Person which controls, is controlled by or is under common control with the Company.  The term “control” means the ownership, directly or indirectly, of more than 50 percent of the voting stock or equity interest of the subject Person.
		

		
			“Applicable Laws” " means all applicable federal, state and local laws, and the rules, regulations, guidance, guidelines, specifications and requirements of any applicable federal, state and local governmental and regulatory authorities and agencies in effect from time to time, including those relating to the regulations and guidelines of the FDA, the Food, Drug, and Cosmetic Act and, as applicable, accepted standards of Good Clinical Practice ("GCP") and International Conference on Harmonization ("ICH") guidelines that may be applicable to Services, related to the manufacture, marketing, promotion, distribution (including storage, handling and transportation) and sale of the Products, including the Federal Food, Drug, and Cosmetic Act (21 U.S. C. §§ 301 et seq.), the Federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)) and implementing safe harbor regulations, the Foreign Corrupt Practices Act, the FDA Guidance for Industry – Supported Scientific and Educational Activities, the American Medical Association Guidelines on Gifts to Physicians from Industry, the AdvaMed Code on 
		

		 

 

		Interactions with Health Care Professionals, all applicable provisions of the Social Security Act (including the obligations of disclosure and reporting), Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical Health Act of 2009, the Physician Payment Sunshine Act (42 U.S.C. § 1320-7h), the Physician Self-Referral Act (42 U.S.C. §1395nn), all federal and state device marketing laws, fraud and abuse statutes, anti-kickback, transparency reporting, insider trading, confidentiality, privacy, discrimination, data protection, consumer protection, and false claims statutes, and their respective implementing rules and regulations, all as may be amended from time to time. 
		

		
			“Person” means any natural person, corporation, unincorporated organization, partnership, association, joint stock company, joint venture, trust or government, or any agency or political subdivision of any government, or any other entity.
		

		
			“Term” means the period commencing on September 15, 2018 and continuing for the period during which this Agreement is in effect.
		

			
	
			
				 2.
			Effect of Termination of Employment Agreement. Consultant acknowledges and agrees that as of the Resignation Date, the Employment Agreement has terminated and that all obligations imposed on either party under the Employment Agreement have ceased effective as of the Resignation Date, except as otherwise expressly provided in the Employment Agreement.  Notwithstanding the foregoing, Consultant agrees that Sections 5.8(a), 5.8(b), 6, 7, 7.1(a), 7.1(b), 7.1(c), 7.1(d), 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 9, 10, 11, 12, 13, 13.1, 13.2, 13.3, 13.4, 14, 14.1, 14.2, 15, 16, 17, 18, 19, 20, 21, 22, 22.1, 22.2, 22.3, 22.4, 22.5, 23, 24, 25, 26, 27, 28, 29 and 30 of the Employment Agreement shall continue in full force and effect notwithstanding the termination of Consultant's employment with the Company and the termination of the Employment Agreement. 

		
			﻿
		

			
	
			
				 3.
			Engagement as Consultant.  Subject to the terms and conditions of this Agreement, the Company engages the services of the Consultant, and the Consultant hereby accepts such engagement to provide consulting and advisory services to the Company related to the Company’s nonclinical, clinical and regulatory, and scientific strategy, execution of clinical development, safety, and clinical operations plans, as well as execution of the Company’s drug development projects.   The consulting and advisory services provided to the Company by Consultant pursuant to this Agreement include advice on the Company’s compliance with Applicable Laws, submission of drug applications, including INDs and NDAs, response to regulatory agencies, and development of processes and procedures, and such other mutually agreed upon matters as the Company may reasonably request from time to time (collectively, the “Services”).  Consultant will be asked to interact directly with both Company personnel, their agents, representatives and customers, provided that Consultant is not entitled to contract, engage or bind the Company.   Consultant shall, from time to time, during the Term and as reasonably requested by Company, keep Company apprised as to Consultant’s progress in performing his Services and Consultant shall, as requested by Company, prepare detailed and accurate reports with respect thereto. All reports prepared by Consultant pursuant to this Agreement are the property of Company.  Consultant shall provide the Services at such specific times and at such locations as Consultant and Company mutually determine from time to time. 

		
			﻿
		

			
	
			
				 4.
			Term.  The term of the Consultant’s engagement pursuant to this Agreement shall commence on the date hereof and continue until the later of: (i) the completion of all activities and Services, as determined in the Company’s sole judgement; (ii) one year from the date hereof; or (iii) such longer term as the parties mutually agree to in writing; all potentially subject to earlier termination in accordance with the provisions of Section 17 hereof (hereafter, the “Term”). 

			
	
			
				 5.
			Duties and Contacts.  In performing the Services, Consultant shall use his best efforts, skills and abilities to promote the interests of the Company and to diligently and competently perform the duties under this Agreement and always in accordance with Applicable Laws. During the term of this Agreement, the Consultant’s primary contacts at the Company shall be the Company’s Chairman and Chief Executive Officer, and such other 
		

		 

		

			2

		

 

			persons as the Company may designate from time to time by notice to the Consultant.  The Consultant will be solely responsible for determining the means, method, and manner by which he will perform the Services, the time at which those Services will be performed, and the sequence of performance of such Services, subject only to this Agreement. 

			
	
			
				 6.
			Compensation.    Except as provided in section 7 below, the Consultant will be compensated, as the sole compensation for the performance of Services under this Agreement and the Consultant’s observance and performance of all of the provisions of this Agreement, at a rate of Two Hundred US Dollars ($200.00) per hour, up to a maximum of ten (10) hours per week devoted exclusively to Company business.  Any hours exceeding this maximum commitment must be approved by the Company.  Consultant shall send Company detailed monthly invoices which shall be directed to ap@verupharma.com with copy to mgreco@verupharma.com.  Invoices will be paid no later than 45 days after receipt.  Except for any compensation attributable to an exercise of any grant of options as provided in section 7 below, the fees specified in this Section 6 shall be the sole remuneration paid by the Company to Consultant in exchange for the Services provided by Consultant under this Agreement.  

			
	
			
				 7.
			Equity Awards.  In addition to receiving the compensation set forth in section 6 above, and provided Consultant complies with the terms and conditions of this Agreement, the Company shall permit (i) the part of the non-qualified stock option to purchase 300,000 shares of common stock issued to Consultant on August 2, 2017  under the Company's 2017 Equity Incentive Plan that is scheduled to vest on August 2, 2019 (100,000 shares) to vest on such vesting date conditioned on Consultant’s compliance with the terms of this Agreement and Consultant providing Services to Company pursuant to section 4 of this Agreement through such vesting date and permit such part of such stock option, if it so vests, to be exercised in accordance with the terms of the Company's 2017 Equity Incentive Plan and the applicable stock option grant agreement, and (ii) the part of the non-qualified stock option to purchase 86,520 shares of common stock issued to Consultant on December 14, 2017 under the Company's 2017 Equity Incentive Plan that is scheduled to vest on December 14, 2018 (86,520 shares) to vest on such vesting date conditioned on Consultant’s compliance with the terms of this Agreement and Consultant providing Services to Company pursuant to section 4 of this Agreement through such vesting date and permit such part of such stock option, if it so vests, to be exercised in accordance with the terms of the Company's 2017 Equity Incentive Plan and the applicable stock option grant agreement.  Consultant acknowledges and agrees that all other stock options granted to Consultant under any of the Company’s equity incentive plans, including the non-qualified stock option to purchase 99,000 shares of common stock issued to Consultant on May 2, 2018 under the Company's 2018 Equity Incentive Plan that is scheduled to vest on May 2, 2019, May 2, 2020 and May 2, 2021 (99,000 shares total) and the part of the non-qualified stock option to purchase 300,000 shares of common stock issued to Consultant on August 2, 2017  under the Company's 2017 Equity Incentive Plan that is scheduled to vest on August 2, 2020 (100,000 shares), are unvested, shall terminate as of the Resignation Date and may not be exercised.

		
			﻿
		

		
			The consideration specified in this section 7 shall not be deemed "compensation" for purposes of any of the Company's qualified retirement plans or other benefit programs, and payment of this consideration does not entitle Consultant to any retirement plan contributions by the Company for Consultant’s benefit or account.  
		

		
			﻿
		

			
	
			
				 8.
			Reimbursement of Expenses.  All travel plans and travel expenses must be approved in advance by the Company.  Upon submission of proper supporting documentation and in specific accordance with such guidelines as may be established from time to time by the Company, the Consultant shall be reimbursed by the Company for reasonable travel expenses actually and necessarily incurred by the Consultant on behalf of the Company in connection with the performance of Services requested by Company under this Agreement.  A copy of the expense report and supporting documentation should be faxed to the individual designated by the Company 
		

		 

		

			3

		

 

			and the original expense reports and supporting documentation should be sent by mail or hand delivered to the Company.  Consultant shall be expected to provide any equipment as shall be necessary to perform the Services. 

			
	
			
				 9.
			Representations of Consultant; Compliance with Law.

			
	
			
				 (a)
			The Consultant represents and warrants that: (a) Consultant is not a party to, or bound by, any agreement or commitment, or subject to any restriction, including but not limited to agreements related to existing or previous employment containing confidentiality, non-solicitation or noncompete covenants, which now or in the future could interfere with the performance by the Consultant of the Services under this Agreement or to the knowledge of the Consultant may have a possibility of adversely affecting the business of the Company; and (b) to the knowledge of the consultant none of the data or information to be provided to Company by Consultant will violate any patent or other intellectual property right of any Person.

			
	
			
				 (b)
			At all times throughout the duration of the Agreement, Consultant agrees to perform his duties hereunder in accordance with all Applicable Laws, as amended from time to time.  Consultant expressly agrees and acknowledges that he will not, directly or indirectly, offer, pay, promise to pay or authorize the payment of money or anything of value to any governmental official, representative, entity or person, for the purpose of influencing such persons' decisions or actions regarding the Products, the Company or its business activities.

			
	
			
				 (c)
			Consultant hereby represents and warrants that he has not been debarred and is not subject to debarment under the Federal Food, Drug, and Cosmetic Act (21 U.S. C. §§ 301 et seq.), and the rules, regulations, guidelines and requirements of the FDA as may be in effect from time to time, nor is Consultant employed by, or in partnership with, a stockholder in, or otherwise affiliated with a Person who has been so debarred.  Consultant will immediately notify Company in writing in the event any of the foregoing representations and warranties prove to be or become untrue.    

			
	
			
				 (d)
			Consultant represents that he has not been nor is he about to be excluded from participation in the federal Medicare or Medicaid program, Maternal and Child Health Services Block Grant or Block Grants for States for Social Services (collectively, "Federal Health Care Programs").  Consultant agrees to immediately notify Company in writing on receipt of notice of intent to exclude or actual notice of exclusion from any Federal Health Care Program.

			
	
			
				 (e)
			The compensation payable under this Agreement has been determined through good faith arms’ length negotiations and constitutes fair market value for the Services rendered and has not been determined in a manner which takes into account the volume or amount of sales of Company Products or any referrals with respect to any of the Company’s products. 

			
	
			
				 (f)
			The compensation is not being given in exchange for any agreement, explicit or implicit, to purchase, refer patients or recommend the Company’s products or services or that such products be placed on any formulary status.  

		
			﻿
		

			
	
			
				 10.
			Confidentiality.

			
	
			
				 (a)
			Confidential Information.  The Consultant acknowledges that (1) as a result of Consultant’s engagement under this Agreement, the Consultant will obtain knowledge of, and access to, proprietary and confidential information of the Company and its Affiliates, including, without limitation, inventions, discoveries, trade secrets, know-how, technical information, systems, processes, methods, designs, manufacturing practices, specifications, models, formulae, prototypes, samples, laboratory and clinical testing results, compounds financial 
		

		 

		

			4

		

 

			and marketing information, business plans, the identity of customers and suppliers, and the identity of products under development, (collectively, the “Confidential Information”), (2) such information, even though it may be contributed, developed or acquired by the Consultant, constitutes valuable, special and unique assets of the Company developed at significant expense which are the exclusive property of the Company, (3) the restrictions on disclosure and use of Confidential Information set forth below are reasonable and necessary to protect the Company and its Affiliates and are not unreasonably restrictive of any personal rights, and (4) the Company would not enter into this Agreement without the assurance that all Confidential Information will be used for the exclusive benefit of the Company.  Accordingly, the Consultant shall not, at any time, either during or subsequent to the Term of this Agreement (A) use the Confidential Information, except in the performance of Services under this Agreement, and (B) disclose to any Person, any of the Confidential Information without the prior written consent of the Company, except to responsible officers and employees of the Company and its Affiliates and other responsible persons who are in a contractual or fiduciary relationship with the Company and who have a need for such information for purposes in the best interests of the Company; provided that the foregoing restrictions on use and disclosure shall not apply to any Confidential Information which:  (i) at the time of disclosure can be demonstrated to be already known to Consultant as evidenced by written documents in the Consultant’s possession, unless such Confidential Information was obtained in connection with the Consultant’s prior service to the Company or is the subject of another confidentiality agreement with or other obligation of secrecy to the Company or another Person; (ii) at the time of disclosure or subsequent thereto is generally available to the public other than by an act or omission on the part of Consultant; (iii) is acquired from or made available by a third Person that is not bound by a confidentiality agreement with or other obligation of secrecy to the Company or another Person; or (iv) is required to be disclosed pursuant to an order of a court or governmental authority, provided that the Consultant gives the Company prompt written notice of any such requirement so that the Company may seek a protective order or other appropriate remedy and Consultant cooperates with the Company in obtaining such an order or other appropriate remedy at no cost to the Consultant.

			
	
			
				 (b)
			Return of Confidential Information.  Upon the termination of this Agreement, the Consultant shall promptly deliver to the Company all drawings, manuals, letters, notes, notebooks, reports and copies thereof and all other materials relating to the Company’s business, including without limitation any materials incorporating Confidential Information or any Company property or Confidential Information, which are in the Consultant’s possession or control, except that which is legally required to properly keep record of the work that the Consultant has performed for the Company, provided that Consultant shall remain subject to all confidentiality obligations provided herein.

			
	
			
				 (c)
			Trade Secrets.  Notwithstanding the provisions of Section 10(a), the parties agree that nothing in this Agreement shall be construed to limit or negate any statutory or common law of torts or trade secrets, where such law provides Company with broader protection than that provided in this Agreement.  During the term of this Agreement, Consultant shall do what is reasonably necessary to prevent misappropriation or unauthorized disclosure of the trade secrets of Company.  After termination of the Agreement, Consultant shall not use or disclose the trade secrets of Company as long as they remain trade secrets.  Consultant will be immune from criminal and civil liability under any federal or state trade secret law for any disclosure of the Company's trade secret(s) that is made (i) in confidence to an attorney or to a federal, state or local government official solely for the purpose of reporting or investigating a suspected violation of law and/or (ii) in a complaint or other document filed in a lawsuit or other proceeding, provided such filing is made under seal.  If Consultant files a lawsuit alleging retaliation by the Company for reporting a suspected violation of law, Consultant may disclose the relevant trade secret to Consultant's attorney and may use the trade secret information in the court proceeding provided (i) any filing containing the trade secret is made under seal; and (ii) Consultant does not disclose the trade secret, except pursuant to a court order.

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		 

		

			5

		

 

			
	
			
				 11.
			Work Product and Intellectual Property Protection

		
			﻿
		

			
	
			
				 (a)
			Work Product. The Consultant acknowledges and agrees that all right, title and interest in and to all writings, works of authorship, technology, inventions, discoveries, processes, techniques, methods, ideas, concepts, research, proposals, materials and all other work product of any nature whatsoever, that are created, prepared, produced, authored, edited, amended, conceived or reduced to practice by the Consultant individually or jointly with others during the period he provides Services to the Company and which relate in any way to the business or contemplated business, products, activities, research or development of the Company or result from any work performed by the Consultant for the Company (in each case, regardless of when or where prepared or whose equipment or other resources is used in preparing the same) all rights and claims related to the foregoing, and all printed, physical and electronic copies, and other tangible embodiments thereof (collectively, "Work Product"),  as well as any and all rights in and to US and foreign (a) patents, patent disclosures and inventions (whether patentable or not), (b) trademarks, service marks, trade dress, trade names, logos, corporate names and domain names, and other similar designations of source or origin, together with the goodwill symbolized by any of the foregoing, (c) copyrights and copyrightable works (including computer programs), and rights in data and databases, (d) trade secrets, know-how and other confidential information, and (e) all other intellectual property rights, in each case whether registered or unregistered and including all registrations and applications for, and renewals and extensions of, such rights, all improvements thereto and all similar or equivalent rights or forms of protection in any part of the world (collectively, "Intellectual Property Rights"),  shall be the sole and exclusive property of the Company.

			
	
			
				 (b)
			Work Made for Hire; Assignment. The Consultant acknowledges that, by reason of being retained by the Company and providing services to the Company at the relevant times, to the extent permitted by law, all of the Work Product consisting of copyrightable subject matter is "work made for hire" as defined in 17 U.S.C. § 101 and such copyrights are therefore owned by the Company. To the extent that the foregoing does not apply, the Consultant hereby irrevocably assigns to the Company, for no additional consideration, the Consultant's entire right, title and interest in and to all Work Product and Intellectual Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation or dilution thereof, and all rights corresponding thereto throughout the world.  The Company’s rights under this Section 11(b) are in addition to, and not in lieu of, any substantive protections the Company may have under any law.

			
	
			
				 (c)
			Further Assurances; Power of Attorney. During and after his engagement, the Consultant agrees to reasonably cooperate with the Company to (a) apply for, obtain, perfect and transfer to the Company the Work Product as well as any and all Intellectual Property Rights in the Work Product in any jurisdiction in the world; and (b) maintain, protect and enforce the same, including, without limitation, giving testimony and executing and delivering to the Company any and all applications, oaths, declarations, affidavits, waivers, assignments and other documents and instruments as shall be requested by the Company. The Consultant hereby irrevocably grants the Company power of attorney to execute and deliver any such documents on the Consultant's behalf in his name and to do all other lawfully permitted acts to transfer the Work Product to the Company and further the transfer, prosecution, issuance and maintenance of all Intellectual Property Rights therein, to the full extent permitted by law, if the Consultant does not promptly cooperate with the Company's request (without limiting the rights the Company shall have in such circumstances by operation of law). The power of attorney is coupled with an interest and shall not be affected by the Consultant's subsequent incapacity.

			
	
			
				 (d)
			No License. The Consultant understands that this Agreement does not, and shall not, be construed to grant the Consultant any license or right of any nature with respect to any Work Product or 
		

		 

		

			6

		

 

			Intellectual Property Rights or any Confidential Information, materials, software or other tools made available to his by the Company.

		
			﻿
		

			
	
			
				 12.
			Restrictive Covenants.

			
	
			
				 (a)
			Non-competition.  Because of the Company’s legitimate business interest as described herein and the good and valuable consideration offered to Consultant, during the term of this Agreement and for the period of two (2) years beginning on the last day of the Services provided under the Agreement (the “Restricted Period”), whether the Services are terminated at the option of the Consultant or the Company, the Consultant agrees and covenants not to engage in Prohibited Activity that is, or is expected to be competitive with the Company’s drug products under development or any drug products that are acquired or approved for marketing by or on behalf of Company during the term of this Agreement (collectively the “Prohibited Products”); provided, however, that the restriction set forth in this section 12(a) shall not prohibit Consultant during the Restricted Period from engaging in a Prohibited Activity with a legally recognized 501(c)(3) not-for-profit enterprise, which organization may include a university or other similar academic organization, so long as all other terms and conditions of this Agreement are complied with by Consultant including but not limited to the nondisclosure or use of Company Confidential Information, non-solicitation of employees and customers, and protection of the Company’s Work Product and Intellectual Property Rights as provided in Section 11 of this Agreement.

		
			﻿
		

			
	
			
				 (b)
			Prohibited Activity. For purposes of this Section 12, "Prohibited Activity" is activity in which the Consultant contributes his knowledge, services and/or financial support, directly or indirectly, in whole or in part, as an owner, operator, manager, advisor, lender, investor, consultant, agent, employee, partner, director, stockholder, officer, volunteer, intern or any other similar capacity to any entity or person, both within the United States or any other country, that sells, markets, and/or is developing any of the Prohibited Products.  Prohibited Activity also includes activity that may require or inevitably may require disclosure of Company trade secrets or other Confidential Information.  Nothing herein shall prohibit the Consultant from purchasing or owning less than five percent (5%) of the publicly traded securities of any corporation, provided that such ownership represents a passive investment and that the Consultant is not a controlling person of, or a member of a group that controls, such corporation.    Nothing herein shall prohibit Consultant from working for a diversified company, provided that Consultant works in a department of the company or in a capacity that is not competitive with the Company as defined in paragraph 12(a). 

			
	
			
				 (c)
			Non-solicitation of Employees. The Consultant agrees that the Company has made a substantial investment in its employees in order to retain their services and valuable contribution to its business, and to minimize turnover and recruitment training time and cost.  Therefore, to protect this legitimate interest of the Company, the Consultant agrees and covenants not to directly or indirectly, on Consultant’s own behalf or on behalf of any other person or entity, solicit, recruit, attempt to solicit or recruit, or induce the termination of employment of any employee of the Company during the Restricted Period with whom Consultant has substantial contact while providing the Services or while providing services to the Company in any other capacity.

			
	
			
				 (d)
			Non-solicitation of Customers and Other Third-Party Representatives.  The Consultant agrees that the Company has made a substantial investment in order to develop and maintain valuable relationships with its customers, prospective customers, service providers, distributors and other representatives (“Third Party Representatives”).  The Consultant further agrees that the Company has long-standing relationships with the Third-Party Representatives and that but for the Consultant’s employment with the Company, the Consultant would not have had access to or Confidential Information about such Third-Party Representatives.  Consultant understands and acknowledges that because of the Consultant's experience with and relationship to the Company he will have access to the Company’s Third-Party Representatives and learn about much or all of the Company's Third-Party Representatives which is confidential and/or compiled in a 
		

		 

		

			7

		

 

			confidential manner.  "Third-Party Representative Information" includes, but is not limited to, names, phone numbers, addresses, e-mail addresses, pricing information, regulatory strategy, and other information identifying facts and circumstances specific to the Third-Party Representative, whether Confidential Information or otherwise.

		
			﻿
		

		
			The Consultant understands and acknowledges that loss of Third Party Representatives relationships and/or goodwill will cause significant and irreparable harm to the Company. 
		

		
			Therefore, to protect these legitimate interests of the Company, Consultant agrees and covenants, during Restricted Period, not to directly or indirectly, on Consultant’s own behalf or on behalf of any other person or entity, solicit, contact (including but not limited to e-mail, regular mail, express mail, telephone, fax, and instant message), attempt to contact or meet with or provide any products or services to the Company's Third Party Representatives for purposes of offering or providing goods or services similar to or competitive with those offered by the Company.
		

		
			The restrictions in this Section 12(d) shall only apply to:
		

			
	
			
				 (i)
			

			
	
			
			Third Party Representatives the Consultant contacted in any way during the past one (1) year period immediately prior to the termination of this Agreement; or

			
	
			
				 (ii)
			

			
	
			
			Third Party Representatives about whom the Consultant has or had access to trade secret or other Confidential Information.

			
	
			
				 (e)
			Non-interference with Other Business Relationships.  The Consultant agrees and covenants, during the Restricted Period, not to directly or indirectly, on Consultant’s own behalf or on behalf of any other person, interfere with or cause disruption in any way to the Company’s contracts or relationships with its business partners, including, but not limited to, vendors, suppliers, manufacturing sources, and IT consultants.

			
	
			
				 13.
			Non-disparagement. The Consultant agrees and covenants that he will not at any time make, publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments or statements concerning the Company or its businesses, or any of its employees, officers, directors, and existing and prospective customers, suppliers, investors and other associated third parties. 

		
			This Section 13 does not, in any way, restrict or impede the Consultant from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation or order. The Consultant shall promptly provide written notice of any such order to Company’s EVP Legal.
		

			
	
			
				 14.
			Acknowledgement. The Consultant acknowledges and agrees that the services to be rendered by him to the Company are of a special and unique character; that Consultant will obtain knowledge and skill relevant to the Company's industry, methods of doing business and marketing strategies by virtue of Consultant’s Services; and that the restrictive covenants and other terms and conditions of this Agreement are reasonable and reasonably necessary to protect the legitimate business interests of the Company. Consultant further acknowledges and agrees that the appointment and compensation he will receive under sections 6 and 7 of this Agreement reflects, in part, substantial consideration for his obligations and the Company's rights under Sections 10 - 13 of this Agreement; that he has no expectation of any additional compensation, royalties or other payment of any kind not otherwise referenced herein in connection herewith; that he will not be subject to undue hardship by reason of his full compliance with the terms and conditions of Sections 10-13 of this Agreement or the Company's enforcement thereof.

		 

		

			8

		

 

			
	
			
				 15.
			Remedies.  The restrictions and requirements set forth in Sections 10, 12 and 13 are considered by the parties to be reasonable for the purposes of protecting the value of the business of the Company.  The Consultant acknowledges that compliance by Consultant with the restrictions and requirements set forth in Sections 10, 12 and 13 will not prevent Consultant from earning a livelihood.  The Consultant acknowledges that the Company would be irreparably harmed and that monetary damages would not provide an adequate remedy in the event of a breach of any of the provisions of Sections 10, 12 and 13.  Accordingly, the Consultant agrees that, in addition to any other remedies available to the Company, the Company shall be entitled to injunctive and other equitable relief to secure the enforcement of these provisions and shall be entitled to receive reimbursement from the Consultant for all attorneys’ fees and expenses incurred by the Company in enforcing these provisions, should the Company prevail.  It is the desire and intent of the parties that the provisions of Sections 10, 12 and 13 be enforced to the fullest extent permissible under the laws and public policies of the jurisdiction in which enforcement is sought.

			
	
			
				 16.
			Conflicts of Interest.  The Consultant is free to perform services for or to accept employment with any other Person or business during the term of this Agreement provided he will not have any relationship with any Person which could create a conflict of interest between the Consultant on the one hand and the Company or any of its Affiliates on the other without the prior written approval of the Company's CEO and President, and further provided that such other services do not preclude or conflict with his performance of the Services.

			
	
			
				 17.
			Termination.  This Agreement may be terminated upon the occurrence of any of the events set forth in, and subject to the terms of, this Section 17.

			
	
			
				 (a)
			Death.  This Agreement will terminate immediately and automatically upon the death of the Consultant.

			
	
			
				 (b)
			Disability.  This Agreement may be terminated at the Company’s option, immediately upon notice to the Consultant, if the Consultant shall suffer a permanent disability.  For the purposes of this Agreement, the term “permanent disability” shall mean the Consultant’s inability to perform his duties under this Agreement, with or without a reasonable accommodation, for a period of 90 consecutive days or for an aggregate of 120 days, whether or not consecutive, in any twelve-month period (the “Disability Period”), due to illness, accident or any other physical or mental incapacity, as reasonably determined in good faith by the Company, subject to compliance with applicable state and federal laws.

		
			﻿
		

			
	
			
				 (c)
			Cause.  This Agreement may be terminated at the Company’s option, immediately upon notice to the Consultant, upon: (i) breach by the Consultant of any material provision of this Agreement or if Consultant fails to adequately perform the Services; (ii) negligence or willful misconduct of the Consultant in connection with the performance of its duties under this Agreement; (iii) fraud, criminal conduct (as evidenced by the filing of any criminal action against the Consultant) or embezzlement by the Consultant; or (iv) Consultant’s misappropriation for personal use of assets or business opportunities of the Company.  Whether or not cause exists for the termination of this Agreement under this provision 17(c) shall be determined by the Company in its sole judgment, subject only to applicable laws. 

		
			﻿
		

			
	
			
				 (d)
			Without Cause.  This Agreement may be terminated by the Company or the Consultant without Cause at any time upon ten (10) day’s written notice to the other party.  

			
	
			
				 (e)
			Effect of Termination.  In the event of any termination under this Section 17, the Company shall have no further obligation under this Agreement to make any payments to, or bestow any benefits on, the Consultant from and after the date of the termination, other than payments or benefits accrued and due and payable to Consultant prior to the date of the termination.  Notwithstanding termination of this Agreement under this 
		

		 

		

			9

		

 

			section 17, the post-termination obligations provided in paragraphs 10, 12 and 13 shall continue in full force and effect per the terms and conditions of those paragraphs and agreements.  On the effective date of termination of this Agreement for whatever reason, Consultant will immediately (a) cease to engage in performing the Services; (b) cease representing in any manner that he is providing services to the Company as an independent contractor or in another capacity; and (c) return all Company property to the Company.

			
	
			
				 18.
			Security and Access.  The Consultant agrees and covenants (a) to comply with all Company security policies and procedures as in force from time to time including without limitation those regarding computer equipment, telephone systems, facilities access, key cards, access codes, Company intranet, internet, social media and instant messaging systems, computer systems, e-mail systems, computer networks, document storage systems, software, data security, encryption, firewalls, passwords and any and all other Company IT resources and communication technologies (collectively, "Facilities and Information Technology Resources"); (b) not to access or use any Facilities and Information Technology Resources except as authorized by the Company; and (iii) not to access or use any Facilities and Information Technology Resources in any manner after the termination of the Agreement. The Consultant agrees to notify the Company promptly in the event he learns of any violation of the foregoing by others, or of any other misappropriation or unauthorized access, use, reproduction or reverse engineering of, or tampering with any Facilities and Information Technology Resources or other Company property or materials by others.

			
	
			
				 19.
			Miscellaneous.

			
	
			
				 (a)
			Survival.  The provisions of Sections 2, 10, 11, 12, 13 and 14 (including all subsections as applicable) shall survive the termination of this Agreement.

			
	
			
				 (b)
			Entire Agreement.  This Agreement, and the terms and conditions of the Employment Agreement as provided in section 2 above, sets forth the entire understanding of the parties and merges and supersedes any prior or contemporaneous agreements between the parties pertaining to the subject matter hereof.  

			
	
			
				 (c)
			Modification.  This Agreement may not be modified, amended or terminated orally, and no modification, termination or attempted waiver of any of the provisions hereof shall be binding unless in writing and signed by the party against whom the same is sought to be enforced.

			
	
			
				 (d)
			Waiver.  Failure of a party to enforce one or more of the provisions of this Agreement or to require at any time performance of any of the obligations hereof shall not be construed to be a waiver of such provisions by such party nor to in any way affect the validity of this Agreement or such party’s right thereafter to enforce any provision of this Agreement, nor to preclude such party from taking any other action at any time which it would legally be entitled to take.  No provision of this Agreement may be waived other than in writing signed by both parties.

			
	
			
				 (e)
			Successors and Assigns.  Consultant shall not have the right to assign in whole or in part this Agreement or delegate any rights or obligations hereunder without the prior written consent of the Company.  

			
	
			
				 (f)
			Additional Acts.  The Consultant and the Company each agree to execute, acknowledge and deliver and file, or cause to be executed, acknowledged and delivered and filed, any and all further instruments, agreements or documents as may be necessary or expedient in order to consummate the transactions provided for in this Agreement and do any and all further acts and things as may be necessary or expedient in order to carry out the purpose and intent of this Agreement.

		 

		

			10

		

 

			
	
			
				 (g)
			Communications.  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed given if delivered by hand, sent by facsimile transmission with confirmation of receipt, sent via a reputable overnight courier service with confirmation of receipt requested, or mailed by registered or certified mail (postage prepaid and return receipt requested) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice), and shall be deemed given on the date on which delivered by hand or otherwise on the date of receipt as confirmed; provided, however, that any notice of change of address shall be effective only upon receipt.

		
			To the Company:
		

		
			﻿
		

		
			Veru Inc.
		

		
			4400 Biscayne Blvd, Suite 888
		

		
			Miami, FL 33137
		

		
			Attn:  EVP Legal
		

		
			﻿
		

		
			To the Consultant:
		

		
			Robert H. Getzenberg Ph.D
		

		
			358 N. Island Drive, # 106
		

		
			Memphis TN 38103
		

		
			﻿
		

		
			﻿
		

			
	
			
				 (h)
			Severability.  If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, such invalidity or unenforceability shall not affect the validity and enforceability of the other provisions of this Agreement and the provision held to be invalid or unenforceable shall be enforced as nearly as possible according to its original terms and intent to eliminate such invalidity or unenforceability.

			
	
			
				 (i)
			Governing Law.  This Agreement and any disputes hereunder will be governed by and construed in accordance with the laws of the State of Florida, without regard to principles of conflict of laws.  

			
	
			
				 (j)
			Jurisdiction; Venue.  This Agreement shall be subject to the exclusive jurisdiction of the courts of Miami-Dade County, Florida.  Any breach of any provision of this Agreement shall be deemed to be a breach occurring in the State of Florida by virtue of a failure to perform an act required to be performed in the State of Florida, and the parties irrevocably and expressly agree to submit to the jurisdiction of the courts of Miami-Dade County, Florida for the purpose of resolving any disputes among them relating to this Agreement or the transactions contemplated by this Agreement.  The parties irrevocably waive, to the fullest extent permitted by law, any objection which they may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement, or any judgment entered by any court in respect hereof brought in Miami-Dade County, Florida, and further irrevocably waive any claim that any suit, action or proceeding brought in Miami-Dade County, Florida has been brought in an inconvenient forum.

			
	
			
				 (k)
			Independent Contractor.  The parties intend that the relationship of the Consultant to the Company be that of an independent contractor.  Accordingly, except as otherwise required by law, Consultant will not be treated as an employee for federal or state tax purposes but instead will be treated as an independent contractor, and any payments to the Consultant shall be made free of withholding for federal, state and local taxes, including without limitation social security taxes, income taxes, and unemployment compensation taxes.  The Consultant shall be responsible for all federal, state and local taxes relating to amounts received by Consultant under this Agreement.  The Company shall not obtain workers compensation insurance, disability insurance coverage of whatever nature and any other insurance coverage for Consultant's benefit while engaged in Services under this Agreement.  Because Consultant is an independent contractor, Consultant is not eligible for, nor entitled to, and shall not participate in, any of the Company’s benefits, including without limitation, pension, bonus and profit sharing plans, health insurance, life insurance, paid vacation, paid holidays, sick leave and disability 
		

		 

		

			11

		

 

			insurance coverage.  Consultant shall have no right or authorization, express or implied, to assume or create any obligation on behalf of the Company.

			
	
			
				 (l)
			Publication.  Consultant agrees that Consultant will not publish any manuscript or other written document based upon information or data resulting from its performance of Services hereunder for the Company, without the prior written consent of the Company.

			
	
			
				 (m)
			Indemnification.  Consultant hereby agrees to indemnify and hold harmless Company and its directors, officers, employees and agents from, against and in respect of, the full amount established in a final judgment issued by a court of competent jurisdiction (and which is not the subject of a pending appeal) of all liabilities, damages, claims, deficiencies, fines, assessments, losses, taxes, penalties, interest, costs and expenses, including, without limitation, reasonable fees and disbursements of counsel, arising from, in connection with, or incident to any breach or violation of any of the representations, warranties, covenants or agreements of Consultant contained in this Agreement, any claims arising from or in connection with Consultant's performance of Services under this Agreement, and any and all actions, suits, proceedings, demands, assessments or judgments, costs and expenses incidental to any of the foregoing.

			
	
			
				 (n)
			Counterparts. This Agreement may be executed by any of the Parties via facsimile or in portable document format ("pdf"). Facsimile or email transmissions of any executed original document and/or retransmission of any executed facsimile or email transmission shall be deemed to be the same as the delivery of an executed original. At the request of any Party hereto, the other Party shall confirm facsimile or email transmissions by executing duplicate original documents and delivering the same to the requesting Party. This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

			
	
			
				 (o)
			Acknowledgement and Attorney Review.  CONSULTANT FURTHER STATES THAT HE HAS CAREFULLY READ THIS AGREEMENT, HE UNDERSTANDS IT, THAT HE HAS HAD THE OPPORTUNITY TO, HAS BEEN URGED BY THE COMPANY TO, AND HAS HAD THE AGREEMENT REVIEWED BY AN ATTORNEY, THAT HE FULLY UNDERSTANDS ITS FINAL AND BINDING EFFECT, THAT THE ONLY PROMISES MADE TO HIM TO SIGN THE AGREEMENT ARE THOSE STATED IN THE AGREEMENT, AND THAT HE IS SIGNING THIS AGREEMENT VOLUNTARILY.

		
			IN WITNESS WHEREOF, each of the parties hereto has duly executed this Agreement in Miami, Florida as of the date set forth above.
		

			
					
						﻿

				
	
					
						VERU INC.

				
	
					
						By: 

					
					
						 

				
	
					
						﻿

					
					
						Mitchell S. Steiner, MD, FACS

				
	
					
						﻿

					
					
						Chairman, President and CEO

				

		
			﻿
		

			
					
						﻿

					
					
						 

				
	
					
						﻿

				
	
					
						CONSULTANT

				
	
					
						By: 

					
					
						 

				
	
					
						﻿

					
					
						Robert H. Getzenberg Ph.D

				
	
					
						﻿

					
					
						Tax ID #: _________________

				

		
			﻿
		

		
			
		

		 

		

			12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]